EF-009
/ Everfront Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 12, 2026
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial completion date: Dec 2026 ➔ Jun 2030 | Trial primary completion date: Dec 2025 ➔ Dec 2029
Trial completion date • Trial primary completion date • Oncology • Pancreatic Cancer • Solid Tumor
February 19, 2024
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial completion date: Jun 2025 ➔ Dec 2026 | Trial primary completion date: Jun 2024 ➔ Dec 2025
Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
January 18, 2023
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
(clinicaltrials.gov)
- P1/2 | N=30 | Not yet recruiting | Sponsor: Everfront Biotech Co., Ltd. | Trial completion date: Jan 2024 ➔ Jun 2025 | Trial primary completion date: Jan 2023 ➔ Jun 2024
Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
August 18, 2021
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
(clinicaltrials.gov)
- P1/2; N=30; Not yet recruiting; Sponsor: Everfront Biotech Co., Ltd.; Trial completion date: Feb 2023 ➔ Jan 2024; Trial primary completion date: Feb 2021 ➔ Jan 2023
Clinical • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
May 08, 2020
A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer
(clinicaltrials.gov)
- P1/2; N=30; Not yet recruiting; Sponsor: Everfront Biotech Co., Ltd.
Clinical • New P1/2 trial
1 to 5
Of
5
Go to page
1